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1. Introduction
   Over the last few decades the increasing pathogenicity 
and capacity to produce β-lactamase enzyme has evolved 
Moraxella catarrhalis (M. catarrhalis) from a benign 
commensal to a genuine pathogen[1,2]. Currently, it is 
considered as one of the common cause of upper and 
lower respiratory tract infections. Though rarely reported, 
it can also cause severe infections including pneumonia, 
endocarditis, septicaemia and meningitis etc[1-4]. M. 
catarrhalis also contributes in mixed respiratory tract 
infections with other pathogens such as Streptococcus 
pneumoniae  (S. pneumoniae )  and/or Haemophilus 
influenzae (H. influenzae). In such cases, β-lactamase 
produced by this organism may render ampicillin 
ineffective against susceptible S. pneumoniae and H. 
influenzae[5]. 
   Sweden was the first country to report the presence 
of β-lactamase in M. catarrhalis in 1977[6]. Since then 
β-lactamase production has been reported from various 
countries with increasing frequency (even above 90%)[7-9]. 
Though it remains rare, reports of increasing resistance to 
other oral antibiotics useful to treat community acquired 
respiratory tract infections (CARTI) are also documented in 
M. catarrhalis[10,11].
   Information regarding frequency of β-lactamase 
production in M. catarrhalis is limited from Pakistan. 
A study from Pakistan reported 93.5% ampicillin 
susceptibility in M. catarrhalis but authors did not report 
β-lactamase activity in those isolates[12]. Another study 
reported 68.7% β-lactamase production in M. catarrhalis. 
However this study had the limitations of small sample 
size and use of less sensitive filter paper acidometric 
test for β-lactamase detection[13]. The local antimicrobial 
susceptibility data of other oral antibiotics used for 
CARTI against M. catarrhalis is also missing. Surveillance 
to monitor shifting trends in resistance is vital as it 
ultimately influences the selection of antimicrobial agents 
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available for use against a particular organism. Therefore, 
this study aimed to assess the frequency of β-lactamase 
production in M. catarrhalis and also drug resistance 
against ampicillin, erythromycin, ciprofloxacin and 
tetracycline, so as to guide empirical therapy in CARTI. 
2. Material and methods
   This cross sectional study was conducted from January 
2010 to December 2010 in the clinical microbiology 
laboratory of Aga Khan University Hospital (AKUH). The 
AKUH laboratory has an extensive network of more than 
200 collection units throughout Pakistan. Through this it 
caters a vast outpatient population across the country. 
2.1. Respiratory specimens
   Clinical respiratory specimens (sputum, tracheal 
aspirate, bronchoalveolar lavage, middle ear fluid, 
nasopharyngeal swab/aspirate and sinus aspirate) from 
community that were received in AKUH laboratory for 
culture and sensitivities during study period were 
included. 
2.2. Isolation of M. catarrhalis
   The identification of the M. catarrhalis was confirmed 
by colony morphology, Gram stain appearance and 
conventional biochemical tests such as positive oxidase, 
catalase, and DNAase test. Clinical isolates were saved in 
glycerol-phosphate buffer at -80 °C. Duplicate samples 
from same patient were excluded. Demographic data 
including gender and age and seasonal distribution were 
also noted. 
2.3. Antimicrobial susceptibility testing
   Ampicillin, erythromycin, ciprofloxacin, and tetracycline 
powder were obtained from Sigma-Aldrich, UK. Minimum 
inhibitory concentrations (MICs) of the antimicrobials 
were performed according to agar dilution method 
recommended by British Society for Chemotherapy (BSAC)
[14]. Agar plates were prepared with the antimicrobials to 
be tested incorporated in the media supplemented with 
5% defibrinated blood in double dilution series. Bacterial 
suspension 104 CFU/spot was prepared and applied 
by the multipoint inoculator. For testing ampicillin, 
inoculum of 106 CFU was used. Plates were incubated 
at 37 °C aerobically for 18 h. MIC breakpoints provided 
by the BSAC[15] were used for interpretation and isolates 
were categorized as being sensitive (S), intermediately 
susceptible (I), or resistant (R).
   Interpretation of the MIC breakpoints was as follows: 
Ampicillin: S≤1 mg/L, R>1 mg/L; Ciprofloxacin: S≤0.5 mg/
L, R>0.5 mg/L; Tetracycline: S≤1 mg/L, I=2 mg/L, R≥2 mg/
L; Erythromycin: S≤0.25 mg/L, I=0.5 mg/L, R≥0.5 mg/L. 
   β-Lactamase production was detected by nitrocefin 
(Oxoid) test. The reference strains used for quality 
control included S. pneumoniae ATCC strain 49619 and 
Staphylococcus aureus ATCC strain 29213. MICs were 
calculated as MIC50 and MIC90 (MIC causing inhibition of 50% 
and 90% of isolates, respectively).
2.4. Data management and statistical analysis
   Data was entered and analysed by the statistical 
software SPSS version 19.0. Frequencies with percentages 
for age and seasonal distribution, β-lactamase production 
and resistance for each drug were computed.
2.5. Ethical approval
   This study was approved by the Ethics Review 
Committee of the Aga Khan University, Pakistan.
3. Results
   A total of 4 440 respiratory specimens were received 
during study period. Out of these, 30% (1 333) were reported 
positive for respiratory pathogens. About 60% (2 680) 
specimens were received from male patients.
   A total of 97/1 333 clinical respiratory specimens yielded 
growth of M. catarrhalis. Amongst studied isolates of M. 
catarrhalis, 71% (69) were from male and 65% (63) were 
recovered from patients aged greater than 65 years. The 
age distribution is shown in Table 1.
Table1
Distribution of M. catarrhalis isolates (n=97) among different age 
groups. 
Age range in years Number (%)
0-15 11 (11.5) 
16-30 11 (11.5) 
31-45 12 (12.0) 
46-65 24 (25.0) 
>65 39 (40.0) 
   Majority of isolates (50.5%, 49) were grown in the winter 
months (November-February) with the peak incidence in 
the month of January (Figure 1). β-Lactamase production 
was detected in 84.5% (81) of isolates, which correlated well 
with the high ampicillin MIC among them. Ninety-seven 
percent of isolates were found susceptible to erythromycin 
with MIC90 of 0.12 mg/L and ninety-six percent susceptible 
to tetracycline with MIC90 of 1 mg/L. All isolates were 
susceptible to ciprofloxacin. The MIC distribution for the 
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four antibiotics tested is given in Table 2.
Table 2
Distribution of MICs (µg/mL)) for antimicrobials tested against M. 
catarrhalis isolates (n=97).
MIC Ampicillin Ciprofloxacin Tetracycline Erythromycin
128 - - - -
64 2 - - -
32 3 - - -
16 4 - - -
8 17 - 1 -
4 21 - 2 -
2 34 - 1 -
1 9 - 10 2
0.5 4 3 57 1
0.25 - 2 13 1
0.125 3 5 8 41
0.06 - 11 5 40
0.03 - 32 - 12
0.015 - 44 - -
MIC90 8 0.06 1 0.125
MIC50 2 0.03 0.5 0.06
MIC range 0.125-64 0.015-0.5 0.06-8 0.03-1
Sensitive (%) 15.5 100 96 97
BSAC break points of MICs for ampicillin (mg/L): S≤1, R>1, 
ciprofloxacin (mg/L): S≤0.5, R>0.5, tetracycline (mg/L): S≤1, I=2, 
R≥2 and erythromycin (mg/L): S≤0.25, I=0.5, R≥0.5.
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Figure 1. Monthly rate of isolation of M. catarrhalis.
4. Discussion 
   This study suggests that empirical use of ampicillin/
amoxicillin in CARTI would miss β-lactamase producing 
M. catarrhalis strains and may lead to treatment failure. 
It may also hamper the treatment of certain concomitant 
organisms, such as penicillin susceptible S. pneumoniae and 
H. influenzae in cases of co-infection[1,5].
   This study demonstrates that frequency of β-lactamase 
production among M. catarrhalis is entirely consistent with 
what reported globally[7-9]. Previous study from Pakistan 
reported 68.7% β-lactamase production. However, in that 
study they used less sensitive acidometric test for enzyme 
detection[13]. Increasing frequency of enzyme production was 
reported from the neighbouring country India. Larson et al. 
reported enzyme production in 68% isolates in 1999 and Anita 
et al. demonstrated 86% of isolates with enzyme activity in 
2011[16-17]. 
   In this study, high ampicillin MIC correlates well with high 
β-lactamase production. Previously published work from 
Pakistan reported 93.5% susceptibility to this drug. However, 
that study had major limitation that authors did not test the 
β-lactamase production in their isolates by the standard 
method[12].
   Another important and promising finding of our study 
is that, resistance to other commonly used oral antibiotics 
in CARTI such as tetracycline and erythromycin remained 
low. Our finding regarding the tetracycline resistance is 
comparable to those obtained from most Asia pacific regions 
(3.2%) except Taiwan where it is around 19%[9,18]. Similarly 
macrolide resistance is comparable to China 5.8%, however 
it is much lower than that reported previously from Pakistan 
(25%)[7,12].
   Although ciprofloxacin is an accessible over the counter 
drug in Pakistan and easily available with or without a 
prescription, fortunately none of the isolate was found to be 
ciprofloxacin resistant. This finding is consistent with other 
reports published globally[7-9]. Though Tabussum et al. from 
Karachi reported 7% and a study from India reported 20% 
ciprofloxacin resistance[12,19].
   Globally, recovery of majority of the isolates from 
respiratory samples from male patients was also observed in 
this study[20]. We also found that M. catarrhalis infections 
are more frequent among older age group. Similar finding 
was reported from India and Nepal[20,21]. The predilection of 
CARTI in the older age group has been studied and several 
reasons have been proposed including age related changes 
in systemic immunity, respiratory tract mucosal changes due 
to smoking and several other co-morbidities[1,2,22]. 
   Majority of isolates were recovered in winter season, which 
is similar to finding of others[20-22]. A viral co-infection 
has been anticipated as the mechanism for the seasonal 
variation, it causes weakening of local immunity thereby 
promoting infection by these pathogens[22].
   This study is limited by its inability to perform molecular 
detection of BRO 1 and 2 for identification of β-lactamase 
enzymes. But it may be anticipated that majority were BRO 1 
β-lactamase enzyme as they had high MICs for ampicillin[23]. 
   In summary, result  of  this study supports the 
recommendation of BSAC in 2011 that clinical laboratories are 
no more required to check the susceptibility of ampicillin 
against M. catarrhalis and should report them resistant[24]. 
Therefore appropriate alternative antibiotic should be 
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selected empirically in regard of treating CARTI. Finally we 
emphasize the judicious use of antibiotics in this region and 
continued surveillance to detect emerging resistance.
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